Abstract
Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.
| Original language | English |
|---|---|
| Pages (from-to) | 595-604 |
| Number of pages | 10 |
| Journal | Immunotherapy |
| Volume | 10 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jun 2018 |
Bibliographical note
Funding Information:Brittany E Givens acknowledges fellowship support from the Alfred P. Sloan Foundation, the University of Iowa Graduate College and the National GEM Consortium. Aliasger K Salem acknowledges support from NIH P30 ES005605, U01ES027252 01, and the Lyle and Sharon Bighley Chair of Pharmaceutical Sciences. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2018 Future Medicine Ltd.
Keywords
- CpG-ODN
- Th1 cytokines
- Th2 cytokines
- allergic asthma
- nanoparticles
- prophylactic treatment
- therapeutic treatment
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology